#drug-development

#drug-development

The origins of medications in modern medicine pose existential questions, especially when treatments become ineffective.

A new class of drugs may treat chronic pain effectively without the addictive properties of opioids.

An experimental treatment shows promise in delaying Alzheimer's symptoms in at-risk individuals, raising concerns about funding halting patient access.

Trikafta's development exemplifies successful collaboration in American biomedical research between public and private sectors, transforming cystic fibrosis treatment.

The rapid FDA approval of Trikafta significantly improved treatment options for children with cystic fibrosis.

Young researchers are innovating in cancer drug development, focusing on pioneering techniques like cancer reversion to reduce the need for traditional treatments.

Pliant Therapeutics is cutting 45% of its workforce to extend cash runway after halting a major trial due to safety issues.

Unity Biotechnology lays off all employees to reduce financial losses.

The CL1 is the first biological computer using lab-grown neurons to advance drug development and neuroscience.

Scientists mimic Alzheimer's disease using living brain tissue, advancing the pursuit for treatments.

A new study reveals a brain pathway that can help combat anxiety by regulating voluntary breathing, offering potential for future calming drugs.

Tirzepatide's dual receptor activation may contribute to its efficacy in weight loss, while GIP's role is not fully understood yet.

The drug developed at MIT shows promise as a weight loss treatment by enhancing nutrient absorption and regulating hunger hormones.

AI in drug development shows promise but requires cautious optimism and realistic expectations.

Despite excitement, AI has not yet significantly improved drug success rates in clinical trials.

Pfizer has halted the development of danuglipron due to safety concerns, but remains committed to exploring other obesity treatment options.

Understanding the relationship between bacteria and drug efficacy is crucial for improving cancer treatment and drug trial success rates.

AI is used by Sanofi to make unbiased decisions on drug development, as it lacks personal attachments.

A new antibiotic drug, PP353, shows promise in treating severe back pain caused by infections, potentially changing treatment paradigms.

Mental health treatments from the 1950s and 1960s largely remain unchanged, according to critique by Professor David Nutt.

Chromodynamics raised €2M to advance its microscopy technology, aiming to revolutionize biomedical research and speed up drug development processes.

Cargo Therapeutics is laying off nearly all its employees after ceasing drug development due to trial failures, marking a major decline for the biotech firm.

Archon Biosciences aims to revolutionize antibody treatments through innovative protein 'cages' that improve drug binding and efficacy.

A new strategy for analgesic drug development is necessary to prevent opioid addiction and find safer pain relief alternatives.

Journavx offers a new pain management solution without the addiction risks of opioids.

Antimicrobial resistance could lead to 39 million deaths by 2050; urgent U.S. government action is essential to combat this crisis.

Glox Therapeutics is developing precision antibiotics to address antimicrobial resistance in cystic fibrosis.

Antibiotic resistance is escalating, necessitating urgent local drug development, particularly in low- and middle-income countries.

A new era in psychiatric medicine is suggested by the approval of innovative drugs, though not all trials yield positive results.

Pharmaceutical companies are developing next-generation psychedelics to serve as safer psychotherapy treatments, with promising early research on compounds like R-MDMA.